Immune-Stimulatory Effects of Curcumin on the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma.
NF-κB
NF-κB inhibitors
Poly I:C
curcumin
epithelial to mesenchymal transition
head and neck squamous cell carcinoma
modulation of tumor microenvironment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
16 Mar 2021
16 Mar 2021
Historique:
received:
20
01
2021
revised:
11
02
2021
accepted:
12
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
4
4
2021
Statut:
epublish
Résumé
Curcumin is known to have immune-modulatory and antitumor effects by interacting with more than 30 different proteins. An important feature of curcumin is the inhibition of nuclear factor kappa of activated B-cells (NF-κB). Here, we evaluate the potential of curcumin to reverse the epithelial to mesenchymal transition (EMT) of head and neck squamous cell carcinoma (HNSCC) cells as a part of tumor escape mechanisms. We examined the impact of curcumin on the expression of different pro- and antitumoral chemokines in ex vivo HNSCC tumor tissue and primary macrophage cultures. Further, we evaluated the combinatorial effect of curcumin and toll-like receptor 3 (TLR3) agonist Poly I:C (PIC) on NF-κB inhibition and regulatory T-cell (Treg) attraction. Mesenchymal markers were significantly reduced in cancer specimens after incubation with curcumin, with simultaneous reduction of key transcription factors of EMT, Snail, and Twist. Furthermore, a decrease of the Treg-attracting chemokine CCL22 was observed. Additionally, curcumin-related inhibition of NF-κB nuclear translocation was evident. The combination of PIC with curcumin resulted in further NF-κB inhibition, whereas PIC alone contrarily resulted in NF-κB activation. Furthermore, curcumin was more effective in inhibiting PIC-dependent NF-κB activation and Treg attraction compared to known NF-κB inhibitors BAY 11-7082 or caffeic acid phenethyl ester (CAPE). The presented results show, for the first time, the immune-modulating effects of curcumin in HNSCC, with potent inhibition of the Treg-attracting effects of PIC. Hence, curcumin presents a promising drug in cancer therapy as a supplement to already established treatments.
Identifiants
pubmed: 33809574
pii: cancers13061335
doi: 10.3390/cancers13061335
pmc: PMC8001767
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Walter-Schulz Stiftung, Munich, Germany
ID : D.6166
Références
Gastroenterology. 2010 Apr;138(4):1429-40
pubmed: 19909745
Endocrinology. 2005 Mar;146(3):1491-7
pubmed: 15564333
Invest New Drugs. 2019 Oct;37(5):837-848
pubmed: 30465316
Clin Cancer Res. 2013 Mar 15;19(6):1340-6
pubmed: 23271799
Am J Physiol Lung Cell Mol Physiol. 2020 May 1;318(5):L864-L872
pubmed: 32101016
Front Oncol. 2019 Jul 23;9:656
pubmed: 31396482
Oral Oncol. 2011 Sep;47(9):818-26
pubmed: 21745758
Eur J Pharmacol. 2017 Jan 5;794:61-68
pubmed: 27832944
Front Oncol. 2019 Nov 08;9:1100
pubmed: 31788442
Head Neck. 2008 Feb;30(2):251-61
pubmed: 18172882
Clin Exp Immunol. 2018 Oct;194(1):67-78
pubmed: 30229863
Cell. 2010 Apr 2;141(1):39-51
pubmed: 20371344
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Cell Oncol (Dordr). 2019 Aug;42(4):405-421
pubmed: 30980365
Oral Oncol. 2019 Jan;88:29-38
pubmed: 30616794
J Biol Chem. 2007 May 25;282(21):15319-23
pubmed: 17395581
Front Pharmacol. 2019 Jul 30;10:715
pubmed: 31417401
Int Immunopharmacol. 2012 Feb;12(2):368-77
pubmed: 22197802
J Biol Chem. 2005 Jul 1;280(26):24347-55
pubmed: 15860458
Head Neck. 2007 Feb;29(2):120-7
pubmed: 17103408
J Surg Oncol. 2011 May 1;103(6):468-74
pubmed: 21480238
Cancer Res. 2012 May 1;72(9):2162-71
pubmed: 22549946
J Clin Oncol. 2015 Oct 10;33(29):3293-304
pubmed: 26351330
Biotechnol Adv. 2014 Nov 1;32(6):1053-64
pubmed: 24793420
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Pharmacol Ther. 2015 Feb;146:120-31
pubmed: 25281915
Phytother Res. 2018 Jun;32(6):985-995
pubmed: 29480523
Vaccine. 2009 May 26;27(25-26):3401-4
pubmed: 19200817
J Immunother Cancer. 2015 Mar 24;3:6
pubmed: 25806105
Clin Cancer Res. 2008 Jul 15;14(14):4491-9
pubmed: 18628464
Br J Cancer. 2010 Feb 16;102(4):639-44
pubmed: 20087353
Oncoimmunology. 2015 Sep 2;5(3):e1088631
pubmed: 27141345
Int J Biol Macromol. 2019 Jun 1;130:429-436
pubmed: 30797011
Br J Cancer. 2015 Mar 17;112(6):1067-75
pubmed: 25668006
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Cancers (Basel). 2020 Mar 13;12(3):
pubmed: 32183059
Clin Cancer Res. 2007 Feb 15;13(4):1076-82
pubmed: 17317814
Cancers (Basel). 2019 Aug 15;11(8):
pubmed: 31443240
N Engl J Med. 2004 May 6;350(19):1937-44
pubmed: 15128893
J Cell Physiol. 2019 Aug;234(8):12471-12482
pubmed: 30623441
BMC Complement Altern Med. 2006 Mar 17;6:10
pubmed: 16545122
Clin Cancer Res. 2005 Feb 15;11(4):1467-73
pubmed: 15746048
Eur Rev Med Pharmacol Sci. 2018 May;22(9):2564-2571
pubmed: 29771406
J Immunol Methods. 2011 Jun 30;369(1-2):59-68
pubmed: 21513715
Crit Rev Food Sci Nutr. 2017 Sep 2;57(13):2889-2895
pubmed: 26528921
Clin Cancer Res. 2018 Jan 1;24(1):6-13
pubmed: 28751445
Exp Hematol. 2007 Oct;35(10):1495-509
pubmed: 17889719
Anticancer Res. 2015 Dec;35(12):6411-8
pubmed: 26637850
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Oncol. 2014 Sep 20;32(27):2940-50
pubmed: 25154822
Int J Cancer. 2004 Sep 20;111(5):679-92
pubmed: 15252836
J Clin Invest. 1999 Oct;104(8):1041-50
pubmed: 10525042
Anticancer Res. 2001 Jul-Aug;21(4B):2895-900
pubmed: 11712783
Cancer Biol Ther. 2010 Jan;9(1):8-14
pubmed: 19901561
Nat Rev Immunol. 2006 Oct;6(10):715-27
pubmed: 16977338
Nat Immunol. 2006 Feb;7(2):131-7
pubmed: 16424890
Ann N Y Acad Sci. 2009 Aug;1171:436-47
pubmed: 19723087
Cancer Res. 2018 Aug 1;78(15):4292-4302
pubmed: 29853604
Oncotarget. 2015 Feb 20;6(5):2981-91
pubmed: 25671296
J Hepatol. 2015 Sep;63(3):661-9
pubmed: 25937435
Mol Oncol. 2017 Jul;11(7):718-738
pubmed: 28590039
Am J Pathol. 2014 Apr;184(4):1062-1072
pubmed: 24486326